Friday, May 30, 2025

Latest

Cronos: Raymond James Reiterates Price Target After PharmaCann Investment

Yesterday, Cronos Group (TSX: CRON) showed once again that the demand for U.S cannabis assets is high with their strategic investment in one of the larger private operators, PharmaCann. Cronos is investing $110.4 million for a 10.5% potential ownership stake via a call option as Cronos cannot own U.S cannabis assets if they want to keep their shares trading on the tier one exchanges. This deal values PharmaCann at roughly $1.05 billion.

This announcement seems like it has not affected analysts’ outlook on Cronos, with the weighted 12-month price target stuck at C$9.38, or a downside of roughly 13%. There are 12 analysts who cover the company, with two having buy ratings, and seven having hold ratings. One analyst has a sell rating and two have strong sell ratings on the stock. The street high sits at C$14.44 from Raymond James while the lowest comes in at C$8.50.

In Raymond James’ note sent after the news, the firm reiterated their buy rating and price target saying that, “CRON seems to be turning up the heat.” Cronos has had heavy news flow recently and this just adds to their excitement for the company.

First off, they say that PharmaCann itself is a pretty decent asset with 6 production facilities and 23 dispensaries in 6 limited licenses states. Sarugaser says that this “in our view, makes this a wise investment for CRON as it proceeds steadily into the U.S. market.” He also believes that this deal might not end in Cronos acquiring PharmaCann but rather “bears more hallmarks of a strategic investment,” as it’s for only 10.5% of the company currently.

Sarugaser believes that the company is gaining momentum as the company announced on June 4th that it is accelerating its biosynthesis program, he believes that between these two news releases it marks a foundational step in the right direction after being left new-less for so long. He believes that this step is one that will start to “rev up the massive CRON-Altira-Ginkgo marketing machine.” Sarugaser speculates that Cronos CBG might be sold at PharmaCann VeriLife locations.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

First Majestic Makes Second Major Discovery At Santa Elena In Just A Year

Related News

Cronos Group Posts Another Gross Loss For Q2, Replaces CFO

Cronos Group (TSX: CRON) (NASDAQ: CRON) this morning reported their second quarter financial results. Revenues...

Friday, August 6, 2021, 08:34:51 AM

Micron Tech: BMO Drops Price Target To $105

Micron Technology (NASDAQ: MU) has had 4 analysts cut their 12-month price targets recently, prior...

Sunday, October 3, 2021, 03:04:00 PM

Lundin Gold Sees BMO Reiterate $14 Price Target After Production Beat

On January 10th, Lundin Gold Inc. (TSX: LUG) announced its 2021 full-year production results. The...

Saturday, January 15, 2022, 03:21:00 PM

United Airlines: Analyst Estimates For Q1 2021

United Airlines (NASDAQ: UAL) will be reporting their first quarter results on April 19th after...

Sunday, April 18, 2021, 12:36:00 PM

K92 Mining Sees Analysts Reiterate Ratings Following Drill Results

Last week, K92 Mining Inc. (TSX: KNT) reported their Judd Vein System drill results, which...

Sunday, September 5, 2021, 04:50:00 PM